Navigation Links
Manhattan Research Ranks the Top Pharmaceutical Branded Websites by Rx Request Rates
Date:2/4/2008

While Chantix and Cialis Lead, Many Heavily Advertised Brands Lag Behind

NEW YORK, Feb. 4 /PRNewswire/ -- Manhattan Research, a leader in syndicated research and marketing services for the health and pharmaceutical industry, today revealed the top pharmaceutical branded product websites ranked by offline requests by U.S. adult consumers. The product site rankings are based on the comprehensive online consumer research study with 5,112 U.S. adults titled ePharma Consumer(R) v7.0: The Future of Integrated DTC Marketing. In addition to the top product site rankings, the study provides in-depth data on more than 200 leading pharmaceutical product sites including site satisfaction, site search rationales, tools and features desired on product sites, and a wide range of consumer actions taken afterwards.

"Having the most unique visitors is no longer the ultimate goal of a successful pharmaceutical product site," says Mark Bard, president of Manhattan Research. He continues, "Brand teams and agencies are being challenged to demonstrate the economic and strategic value created by these online destinations - beyond the raw number of visitors or page views. After all, if a site is all traffic and no action then what is the strategic value of the site?"

Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests

1. Chantix

2. Cialis

3. Viagra

4. Aciphex

5. Ambien CR

6. Levitra

7. Lamisil

8. Lunesta

9. Wellbutrin XL

10. Ortho Evra

Source: ePharma Consumer(R) v7.0, Manhattan Research, LLC

To learn more about consumer segments of pharmaceutical information seekers, contact Manhattan Research by visiting http://www.manhattanresearch.com/ePC.htm or by emailing sales@manhattanresearch.com.

Some of the additional product sites researched within ePharma Consumer(R) v7.0 include the following: Abilify, Actonel, Advair, Aranesp, Aricept, Avandia, Boniva, Botox, Caduet, Concerta, Crestor, Cymbalta, Depakote, Depo- Provera, Detrol LA, Effexor XR, Enbrel, Flomax, Flonase, Flovent, Fosamax, Gardasil, Glucophage XR, Humira, Humulin, Imitrex, Lantus, Lexapro, Lipitor, Nasacort, Nasonex, Neulasta, Neurontin, Nexium, Norvasc, NuvaRing, Ortho Tri- Cyclen Lo, Paxil, Plavix, Pravachol, Prevacid, Protonix, Provigil, Pulmicort, Restasis, Risperdal, Rozerem, Seasonale, Seroquel, Singulair, Strattera, Tamiflu, Topamax, Toprol XL, Tricor, Valtrex, Vytorin, Yasmin, Yaz, Zocor, Zoloft, Zomig, Zyprexa and Zyrtec.

Please visit http://www.manhattanresearch.com/ePC.htm to download the ePharma Consumer(R) product brochure, request subscription information, and to listen to two audio presentations summarizing highlights from the research.

Manhattan Research

ePharma Consumer(R) v7.0 is a syndicated multi-client study and advisory service focused on key research topics and trends impacting online U.S. consumers seeking pharmaceutical information. The study was fielded in December 2007 among 5,112 U.S. adult consumers. In addition to ePharma Consumer(R), Manhattan Research conducts five additional research studies annually among consumers and physicians in the United States and in Europe: Cybercitizen(R) Health US, Cybercitizen(R) Health Europe, Taking the Pulse(R) US, Taking the Pulse(R) Europe, and ePharma Physician(R). Each study serves a unique purpose and focuses on specific aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analyses among more than 50 consumer therapeutic segments and 25 physician specialist segments.

Contact:

Erica Alexander Martini

212-255-7799

Ealexander@Manhattanresearch.Com


'/>"/>
SOURCE Manhattan Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):